Six new lawsuits against Eli Lilly and Novo Nordisk surfaced this week, all connected to GLP-1 drugs such as Ozempic and Wegovy. None of the claims are public yet, because courts have sealed the filings. For patients taking these medications, that means there is no detail to act on right now, only a growing count of pending cases. This matters because it signals more legal scrutiny of GLP-1 drugs may be coming, even before the specifics are known.
One of these cases, Bernal v. Novo Nordisk A/S, is already underway in court. The public record does not yet show what claims the plaintiff is making against the company. This is common in early stages of litigation, when parties file under seal while the case is being organized. For now, patients following GLP-1 litigation should treat this case as one to watch rather than one to draw conclusions from, since there is nothing in the public docket to describe the allegations.
A separate case, Schropshire v. Eli Lilly and Company, involves a patient who has filed suit against the drugmaker over a GLP-1 medication. As with the Novo Nordisk case, the details of what happened and what the patient is alleging remain sealed. That means readers cannot yet learn whether the claim involves a specific side effect, a labeling issue, or something else tied to the drug. Eli Lilly has not responded publicly to the filing based on what is currently available.
A third lawsuit, Bastinelli v. Novo Nordisk A/S, is pending in federal court and names Ozempic or Wegovy specifically. Filing in federal rather than state court can shape how a case moves forward, including which rules apply to discovery and how long the process takes. Even so, the substance of the complaint has not been made public, so it is not yet possible to say what the patient experienced or what remedy they are seeking. I would suggest checking back as the case progresses, since federal filings often become public in stages.
The Tutt case against Novo Nordisk follows the same pattern, with claims tied to Ozempic or Wegovy that have not yet been unsealed. Because several of these filings involve the same two drugs, it may be tempting to assume they share similar allegations, but there is no public information confirming that yet. Each case is proceeding on its own docket, and the details could turn out to be different from one another. Patience is warranted here, since sealed filings can stay that way for weeks or months before anything is disclosed.
Cummings v. Eli Lilly and Company rounds out the group of patient lawsuits filed against the company this period. Like the Schropshire case, it is pending, and the underlying complaint has not been made public. Two separate patients suing the same company over GLP-1 drugs in the same stretch of time stands out for anyone tracking the volume of litigation, even without knowing what each person is claiming. If more detail becomes available, it should clarify whether these cases involve similar or unrelated concerns.
For now, there is no new information to act on if you take a GLP-1 medication such as Ozempic or one made by Eli Lilly. The most useful step is to keep watching for updates as these cases move through the courts and become unsealed. If you already have questions about a GLP-1 drug you are taking, raise them directly with your prescriber rather than waiting on litigation to explain anything. Court filings and medical guidance serve different purposes, and only one of them is meant to inform your care.
Key details
A lawsuit against Novo Nordisk is underway, but its claims remain undisclosed.
A patient has sued Eli Lilly over a GLP-1 drug, with details still sealed.
One lawsuit against Novo Nordisk over Ozempic or Wegovy is pending, with details sealed.
The Tutt lawsuit against Novo Nordisk over Ozempic or Wegovy remains sealed.
Another patient lawsuit against Eli Lilly over a GLP-1 drug is pending and sealed.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.